Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335811 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
A Phase 1 study of Endocrine Neoplasia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05335811 is a Phase 1 study of Endocrine Neoplasia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05335811, a Phase 1 study of Endocrine Neoplasia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
18F-4FN represents a novel PET agent for imaging inflammation. Acute inflammatory signaling through the TLR axis recruits neutrophils and macrophages to inflammatory sites. Both cells activate the production of high energy reactive oxygen species/reactive nitrogen species (RONS), setting off a cascade that can be leveraged to detect the presence of these inflammatory cells by molecular imaging. 18F-4FN is efficiently oxidized by high energy RONS, leading to retention and accumulation in human neutrophil-like cells in vitro, and at the sites of acute inflammation in vivo. Like 18F-FDG, 18F-4FN clears rapidly through the kidney at 1 hr following i.v. injection
Conditions Studied
Interventions
- DRUG 4-[18F]Fluoro-1-Naphthol
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335811
The ClinicalTrials.gov registry entry for NCT05335811 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endocrine Neoplasia appearing as the primary indexed condition, and to 1 intervention - of which 4-[18F]Fluoro-1-Naphthol is the first listed.
NCT05335811 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05335811 about?
NCT05335811 is a clinical study titled "First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging". 18F-4FN represents a novel PET agent for imaging inflammation. Acute inflammatory signaling through the TLR axis recruits neutrophils and macrophages to inflammatory sites. Both cells activate the production of high energy reactive oxygen species/reactive nitrogen species (RONS), setting off a casca...
What is the current status of trial NCT05335811?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2022-10-06. Estimated completion is 2026-08-31.
What conditions does trial NCT05335811 study?
This clinical trial studies the following conditions: Endocrine Neoplasia.
What interventions are being tested in trial NCT05335811?
The interventions under investigation include: 4-[18F]Fluoro-1-Naphthol (DRUG).
Who is sponsoring clinical trial NCT05335811?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05335811 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.